PD-1 signaling and PD-1 blockade–mediated tumor control are established at microvillar T cell contacts
Science Immunology · 15.05.2026 · 11 (119)
DOI: 10.1126/sciimmunol.adz4983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 15.05.2026. Verfasst von Edward Jenkins und 18 weiteren Autor:innen. Beteiligte Einrichtung: Radcliffe Department of Medicine, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Signal Transduction, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: Wellcome, Marie Sklodowska-Curie Actions, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Lymphocyte activation relies on the integration of signals from multiple receptors at cell-cell contacts, but the spatiotemporal regulation of this process is unclear. Here, we show that programmed cell death protein 1 (PD-1) and T cell receptor (TCR) signals are integrated at nanoscale microvillar close contacts formed during T cell interactions with their targets. PD-1 signaling begins as these contacts form and selectively limits the duration, but not the amplitude, of TCR signaling. PD-1 suppresses TCR activity directly, by locally recruiting Src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP2), and indirectly, by reducing cell-spreading, close-contact formation, and TCR engagement. A PD-1 blocking antibody induced inhibitory signaling when Fc receptor engagement trapped PD-1 at close contacts. Engineering the antibody to prevent PD-1 trapping eliminated these agonistic effects and improved blockade efficacy. These findings identify microvillar contacts as crucial hubs of initial signal integration and provide a framework for optimizing checkpoint immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
- Medical Research Council Translational Immune Discovery Unit, University of Oxford, Oxford, UK.
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
- Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
- Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
ORCID-Profile: Edward Jenkins, Martin Fellermeyer, Daniel F Heraghty, Sumana Sharma, Tanmay Mitra, Mateusz Kotowski, Joseph Clarke, Yuan Lui, Sam Daly, Zach Marin, Debasis Banik, Markus Körbel, Emily Zhi Qing Ng, Ana Mafalda Santos, Michael L Dustin, Simon J Davis, David Klenerman
Förderung
- Wellcome
- Marie Sklodowska-Curie Actions
- Chinese Academy of Medical Sciences
- Royal Society Research Professorship
Zitieren
APA
Jenkins, E., Fellermeyer, M., Heraghty, D. F., Sharma, S., Mitra, T., Kotowski, M., Clarke, J., Lui, Y., Daly, S., Marin, Z., Banik, D., Körbel, M., Ng, E. Z. Q., Lister, T., Santos, A. M., Lee, S. F., Dustin, M. L., Davis, S. J., & Klenerman, D. (2026). PD-1 signaling and PD-1 blockade–mediated tumor control are established at microvillar T cell contacts. Science Immunology, 11(119). https://doi.org/10.1126/sciimmunol.adz4983
Vancouver
Jenkins E, Fellermeyer M, Heraghty DF, Sharma S, Mitra T, Kotowski M, et al. PD-1 signaling and PD-1 blockade–mediated tumor control are established at microvillar T cell contacts. Science Immunology. 2026;11(119). doi:10.1126/sciimmunol.adz4983
BibTeX
@article{Jenkins2026,
author = {Jenkins, Edward and Fellermeyer, Martin and Heraghty, Daniel F and Sharma, Sumana and Mitra, Tanmay and Kotowski, Mateusz and Clarke, Joseph and Lui, Yuan and Daly, Sam and Marin, Zach and Banik, Debasis and Körbel, Markus and Ng, Emily Zhi Qing and Lister, Thomas and Santos, Ana Mafalda and Lee, Steven F and Dustin, Michael L and Davis, Simon J and Klenerman, David},
title = {PD-1 signaling and PD-1 blockade–mediated tumor control are established at microvillar T cell contacts},
journal = {Science Immunology},
year = {2026},
volume = {11},
number = {119},
doi = {10.1126/sciimmunol.adz4983}
}
EUVIMED